Urinary tract infections (UTIs) place a considerable burden on the patient and
are associated with substantial economic cost. Treatment of UTIs is mainly
achieved using antibiotics, however, the rise in antibiotic resistance is
concerning and the use of non-antimicrobial prophylaxis offers alternative
treatment methods.
JohansenTEBottoHCekM. Critical review of current definitions of urinary tract
infections and proposal of an EAU/ESIU classification
system. Int J Antimicrob Agents2011;38Suppl: 64–70
2.
CianiOGrassiDTarriconeRAn economic perspective on urinary tract infection: the “costs of
resignation”. Clin Drug Investig2013;33 (4):
255–261
3.
FoxmanBUrinary tract infection syndromes: occurrence, recurrence,
bacteriology, risk factors, and disease burden.
Infect Dis Clin North Am2014;28 (1):
1–13
4.
GradwohlSEBettcherCMChenowethCEVan HarrisonRZoschnickLB(2011).University of Michigan Health System. UMHS Clinical Guideline.
Urinary tract infection guideline. University of Michigan,
2011 update. http://ocpd.med.umich.edu/sites/default/files/guidelines/uti_0.pdf.
Accessed 13 April 2016.
5.
FoxmanBBrownPEpidemiology of urinary tract infections: transmission and risk
factors, incidence, and costs. Infect Dis Clin North
Am2003;17 (2):
227–241
6.
HootonTMRecurrent urinary tract infection in women.
Int J Antimicrob Agents2001;17 (4):
259–268
EjrnaesKBacterial characteristics of importance for recurrent urinary
tract infections caused by Escherichia coli. Dan Med
Bull2011;58 (4):
B4187
9.
JusticeSSHungCTheriotJA. Differentiation and developmental pathways of
uropathogenic Escherichia coli in urinary tract
pathogenesis. Proc Natl Acad Sci USA2004;101 (5):
1333–1338
10.
FerrySAHolmSEStenlundHLundholmRMonsenTJThe natural course of uncomplicated lower urinary tract infection
in women illustrated by a randomized placebo controlled
study. Scand J Infect Dis2004;36 (4):
296–301
11.
FalagasMEKotsantisIKVouloumanouEKRafailidisPIAntibiotics versus placebo in the treatment of women with
uncomplicated cystitis: a meta-analysis of randomized controlled
trials. J Infect2009;58 (2):
91–102
12.
LewisKPlatforms for antibiotic discovery. Nat
Rev Drug Discov2013;12 (5):
371–387
13.
SanchezGVBabikerAMasterRNLuuTMathurABordonJAntibiotic Resistance among Urinary Isolates from Female
Outpatients in the United States in 2003 and 2012.
Antimicrob Agents Chemother2016
14.
OteoJBautistaVLaraN. Parallel increase in community use of fosfomycin and
resistance to fosfomycin in extended-spectrum beta-lactamase
(ESBL)-producing Escherichia coli. J Antimicrob
Chemother2010;65 (11):
2459–2463
15.
KhamenehBDiabRGhazviniKFazly BazzazBSBreakthroughs in bacterial resistance mechanisms and the
potential ways to combat them. Microb
Pathog2016;9532–42
16.
TasdemirSTasdemirCVardiN. Intravesical hyaluronic acid and chondroitin sulfate
alone and in combination for urinary tract infection: assessment of
protective effects in a rat model. Int J
Urol2012;19 (12):
1108–1112
17.
Flores-MirelesALWalkerJNCaparonMHultgrenSJUrinary tract infections: epidemiology, mechanisms of infection
and treatment options. Nat Rev Microbiol2015;13 (5):
269–284
